Ones To Watch News
Refine Search
Biotechnology
Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million Series C financing. 14 January 2025
Pharmaceutical
US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS trial of linsitinib in patients with active, moderate to severe thyroid eye disease (TED). 14 January 2025
Biotechnology
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual JP Morgan Healthcare Conference in San Francisco, California. 14 January 2025
Biotechnology
US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced the achievement of a success milestone for one of the targets in its research collaboration with French pharma major Sanofi to develop in vivo CRISPR-based therapeutics. 14 January 2025
Pharmaceutical
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have unveiled Phase II trial data for their obesity drug HRS9531, a GLP-1/GIP receptor dual agonist. 14 January 2025
Biotechnology
French immunotherapy company OSE Immunotherapeutics has appointed Dr Sonya Montgomery as chief development officer. She will serve on the OSE executive committee in a strategic move that will enhance the company’s development capabilities. 14 January 2025
Biotechnology
US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli Lilly advance MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). 13 January 2025
Biotechnology
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with chronic immune-mediated diseases, has announced its launch with $120 million in funding. 13 January 2025
Biotechnology
UK pharma major GSK is to acquire IDRx, a Boston, USA-based, clinical-stage biopharma developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). 13 January 2025
Pharmaceutical
Shares of USA-based Intra-Cellular Therapies leapt almost 36% to $128.85 in pre-marker activity today, as rumors of a takeover bid were confirmed. 13 January 2025
Biotechnology
US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs). 13 January 2025
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Biotechnology
Maryland, USA-based Veralox Therapeutics has picked up an option to acquire Nudge Therapeutics, along with its portfolio of preclinical cGAS inhibitor compounds. 10 January 2025
Biotechnology
German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. 10 January 2025
Biotechnology
USA-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences (HKEX: 02162) have joined forces to launch Timberlyne Therapeutics. 10 January 2025
Biotechnology
European biotech start-ups Numab Therapeutics and AnaCardio have raised new funding to advance their pipelines, adding positive momentum to the sector at the start of the new year. 10 January 2025
Biotechnology
USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. 10 January 2025
Biotechnology
Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research collaboration and option to license agreement (RCO) with Japan’s Chugai Pharmaceutical. 9 January 2025
Biotechnology
Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million Series C financing. 14 January 2025
Pharmaceutical
US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS trial of linsitinib in patients with active, moderate to severe thyroid eye disease (TED). 14 January 2025
Biotechnology
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual JP Morgan Healthcare Conference in San Francisco, California. 14 January 2025
Biotechnology
US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced the achievement of a success milestone for one of the targets in its research collaboration with French pharma major Sanofi to develop in vivo CRISPR-based therapeutics. 14 January 2025
Pharmaceutical
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have unveiled Phase II trial data for their obesity drug HRS9531, a GLP-1/GIP receptor dual agonist. 14 January 2025
Biotechnology
French immunotherapy company OSE Immunotherapeutics has appointed Dr Sonya Montgomery as chief development officer. She will serve on the OSE executive committee in a strategic move that will enhance the company’s development capabilities. 14 January 2025
Biotechnology
US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli Lilly advance MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). 13 January 2025
Biotechnology
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with chronic immune-mediated diseases, has announced its launch with $120 million in funding. 13 January 2025
Biotechnology
UK pharma major GSK is to acquire IDRx, a Boston, USA-based, clinical-stage biopharma developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). 13 January 2025
Pharmaceutical
Shares of USA-based Intra-Cellular Therapies leapt almost 36% to $128.85 in pre-marker activity today, as rumors of a takeover bid were confirmed. 13 January 2025
Biotechnology
US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs). 13 January 2025
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Biotechnology
Maryland, USA-based Veralox Therapeutics has picked up an option to acquire Nudge Therapeutics, along with its portfolio of preclinical cGAS inhibitor compounds. 10 January 2025
Biotechnology
German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. 10 January 2025
Biotechnology
USA-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences (HKEX: 02162) have joined forces to launch Timberlyne Therapeutics. 10 January 2025
Biotechnology
European biotech start-ups Numab Therapeutics and AnaCardio have raised new funding to advance their pipelines, adding positive momentum to the sector at the start of the new year. 10 January 2025
Biotechnology
USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. 10 January 2025
Biotechnology
Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research collaboration and option to license agreement (RCO) with Japan’s Chugai Pharmaceutical. 9 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze